RECURSION PHARMACEUTICALS, INC. (RXRX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, RECURSION PHARMACEUTICALS, INC. reported revenue of $74.68M, up 26.9% from the prior year. The company ran a net loss, with a net margin of -863.4%. It held $1.47B in total assets against $343.26M in total liabilities.
Key ratios (FY2025)
-867.9%
Operating margin
-863.4%
Net margin
-57.0%
Return on equity
+26.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $74.68M | $58.84M | $44.58M | $39.84M | $10.18M | $3.96M | $2.32M | — |
| Cost of Revenue | $70.95M | $45.24M | $42.59M | $48.27M | $0 | $0 | — | — |
| Operating Income | -$648.13M | -$479.00M | -$350.06M | -$245.73M | -$182.78M | -$84.61M | -$62.44M | — |
| Net Income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -$186.48M | -$87.01M | -$61.88M | — |
| EPS (Diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 | $-3.99 | $-2.87 | — |
| Total Assets | $1.47B | $1.45B | $653.70M | $701.29M | $610.35M | $298.58M | — | — |
| Total Liabilities | $343.26M | $413.82M | $190.26M | $215.48M | $67.41M | $56.56M | — | — |
| Shareholders' Equity | $1.13B | $1.03B | $463.44M | $485.81M | $542.94M | -$206.29M | -$124.27M | -$63.85M |
| Cash & Equivalents | $743.29M | $594.35M | $391.56M | $549.91M | $285.12M | $262.13M | — | — |
| Operating Cash Flow | -$371.81M | -$359.17M | -$287.78M | -$83.52M | -$158.61M | -$45.40M | -$57.04M | — |
| Capital Expenditures | $6.47M | $13.70M | $11.96M | $37.06M | $39.80M | $5.83M | $3.91M | — |
| Shares Outstanding | 447.45M | 274.21M | 207.85M | 175.54M | 125.35M | 21.78M | 21.57M | — |